Key result
Acetazolamide and dichlorphenamide target specific BK channel isoforms in skeletal muscle to effectively treat hypokalemic and hyperkalemic periodic paralysis.
Highlights the role of BK channel diversity in skeletal muscle and its implications for targeted drug therapy in neuromuscular disorders.
On November 2013 a review entitled “A BK (Slo1) channel journey from molecule to physiology”, authors: Contreras GF, Castillo K, Enrique N, Carrasquel-Ursulaez W, Castillo JP, Milesi V, Neely A, Alvarez O, Ferreira G, González C, Latorre R was published on Journal “CHANNELS”. Prof. Ramon Latorre of Centro Interdisciplinario de Neurociencia de Valparaíso, Facultad de Ciencias, Universidad de Valparaíso, Chile, and co-authors in their review paper deal with the hallmarks of big Ca2+-activated K+ (BK) channel biophysics and its physiological impact on specific cells and tissues, highlighting its relationship with auxiliary subunit expression (Contreras et al., 2013). However, the molecular aspects and role of skeletal muscle BK channel subtypes were not extensively discussed. One of the scientific programs running in our labs is related to the role of BK channel in native skeletal muscle fibers using patch-clamp in excised patch mode and molecular biology techniques. Briefly, in skeletal muscle the opening of BK channel triggered by depolarization and Ca2+ ions increases the duration of the hyperpolarization phase between bursts of action potentials reducing the firing capability during discharge. One important aspect concerns the BK channel diversity in the tissues. In fact, the functional diversity of BK channel is established by the association of the alpha subunit encoded by KCNMA1 gene with auxiliary 1-4 subunits encoded by KCNMB1-4 genes with the contribution of novel subunits (Contreras et al., 2013; Toro et al., 2014; Torres et al., 2014). In skeletal muscle we established that the alternative splicing of the KCNMA1/slo1 gene is the main mechanism regulating BK channel diversity in the muscle phenotypes (Shipston, 2001; Tricarico et al., 2005; Dinardo et al., 2012). Slow-twitch rat fibers show an elevated expression/activity of BK channel which is characterized by a low sensitivity to Ca2+ions and absence of response to BK channel openers such as acetazolamide (Tricarico et al., 2004, 2005). In contrast, BK channel of fast-twitch rat fibers show a low expression/activity, high Ca2+ions sensitivity and response to drugs (Tricarico et al., 2004, 2005). The analysis of rat slo1 gene at N1 and C1-C6 splice sites found the presence of 5 different variants in both fast-twitch and slow-twitch muscles, such as e17 in C1, e22 and +29 aa in C2 and rSlo27 and rSlo0 in C4 (Dinardo et al., 2012). Real time-PCR experiment showed that e22 and rSlo0 variants are markedly expressed in fast-twitch muscle, the rSlo27 is found in the slow-twitch muscle giving rise to different molecular BK channel (Dinardo et al., 2012). In skeletal muscle, the different types of BK channel play muscle-specific roles contributing to the calcium-dependent phenotype determination/adaptation to disuse which is associated with changes of contractile properties and metabolism. After 3-14 days of muscle immobilization of the rat, in parallel with the slow-to-fast phenotype transition of the fibers, the BK channel of slow-twitch fibers acquires properties similar to those of fast-twitch fibers (Tricarico et al., 2005). Abnormally enhanced BK channel current is observed during aging in fast-twitch fibers which are characterized by muscle disuse and fast-to slow twitch fibers transition (Tricarico et al., 1997; Pierno et al., 2014). In addition, other than regulating fiber excitability and muscle phenotype transition during disuse, the BK channel sense extracellular K+ ion concentration regulating cell remodeling during hyperkalemia as observed in cell line and in a rat model of ischemia-reperfusion associated with hyperkalemia (Tricarico et al., 2002, 2013). The presence of different types of BK channel in skeletal muscle may have implications for drug-based therapy of neuromuscular disorders, including hyper/hypokalemic periodic paralysis (PP). HypoPP is characterized by insulin-induced paralysis and hypokalemia associated with mutations of SCN5A and CACNA1 genes, respectively encoding for the voltage-dependent Na+-channel and Ca2+-channel carrying abnormal H+/Na+ currents, and down-regulation of inwardly-rectifying K+-channels (Kir) in fast-twitch muscle (Tricarico et al., 2003, 2008, 2011; Jovanović et al., 2008). HyperPP is associated with gain-of-function mutations of the SCN5A gene with persistent Na+ influx and depolarization, which in turn inactivates the Na+-channel and lead to the efflux of K+ ions carried by Kv/BK channels with hyperkalemia and paralysis (Cannon, 2015). Acetazolamide and dichlorphenamide act in hypoPP at micromolar concentrations of opening the BK channel in excised macropatches from fast-twitch rat fibers and are effective in repolarizing the fibers in animal models of hypoPP and in hypoPP patients (Tricarico et al., 2004, 2011; Jurkat-Rott et al., 2009; Imbrici et al., 2016). In addition, acetazolamide and dichlorphenamide inhibits the membrane bound carbonic anhydrase enzymes CAIV/XIV and the CAII cytosolic form with change in the intra/extra cellular [H+]. This affects the activity of extra/intracellular proton exchange mechanisms. In our experiments acetazolamide inhibits the monocarboxylate transporter reducing the efflux of lactate thereby preventing myopathy (Tricarico et al., 2008; Tricarico and Conte Camerino, 2011). The activity of ion channels showing pH-sensitive gating may be also affected by acetazolamide and dichlorphenamide. In this respect, hypoPP patients with the histidine substitutions are responsive to the drug while those with glycine substitutions are not alleviated by lowering intracellular pH and have not benefited by acetazolamide (Tricarico and Conte Camerino, 2011). Clinical investigation recently showed that dichlorphenamide is effective in reducing the average number of attacks per week in hypoPP patient but not in hyperPP (Sansone et al., 2016). Therefore, dichlorphenamide can be a preferential drug in hypoPP patients, including those not responsive to acetazolamide, while acetazolamide is also effective in hyperPP and myotonia. In conclusion, different factors may affect the drug responses of acetazolamide and dichlorphenamide in neuromuscular disorders. Among these, the expression of pH-sensitive mutant subunits in the muscles can play a role. Alternatively, a particular combination of BK subunits that include the slo27 may lead to the formation of BK channel unresponsive to the drugs. Drugs specifically targeting the slow-type BK channel or the fast-twitch type may be helpful in disorders affecting specific muscle phenotype.
No takes yet. Share an insight, caveat, or question.
Tricarico et al. (2017) conducted an editorial in Periodic paralysis. Acetazolamide and dichlorphenamide was evaluated. Acetazolamide and dichlorphenamide target specific BK channel isoforms in skeletal muscle to effectively treat hypokalemic and hyperkalemic periodic paralysis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: